{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:33:55Z","timestamp":1792812835983,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00748-4","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:53:06Z","timestamp":1745221986000},"page":"977-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation"],"prefix":"10.1007","volume":"14","author":[{"given":"Masaaki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Shichijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Suzuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Eriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Yukitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-3183","authenticated-orcid":false,"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"5","key":"748_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390.","journal-title":"Lancet Neurol"},{"issue":"3","key":"748_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM197701202960301","volume":"296","author":"KV Toyka","year":"1977","unstructured":"Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977;296(3):125\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"748_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","volume":"55","author":"J McConville","year":"2004","unstructured":"McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580\u20134.","journal-title":"Ann Neurol"},{"issue":"10","key":"748_CR4","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig. 2018;128(10):4372\u201386.","journal-title":"J Clin Investig"},{"issue":"7","key":"748_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"5","key":"748_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378","volume":"21","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Vu T, Li G, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase\u00a03 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics. 2024;21(5):e00378.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"748_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase\u00a03 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"key":"748_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14:19\u201327.","journal-title":"Clin Exp Neuroimmunol"},{"key":"748_CR9","doi-asserted-by":"crossref","unstructured":"Tanaka K, Yoshikawa M, Inoue Y, et al. Efgartigimod successfully ameliorated acute exacerbation of myasthenia gravis with anti-muscle-specific kinase antibodies. Intern Med. 2025;64(6):925\u20139.","DOI":"10.2169\/internalmedicine.3726-24"},{"issue":"7","key":"748_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139.","journal-title":"Neurology"},{"issue":"3","key":"748_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"3","key":"748_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y, et al. Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan. Neurol Clin Pract. 2024;14(3):e200276.","journal-title":"Neurol Clin Pract"},{"issue":"12","key":"748_CR13","volume":"15","author":"K Kawama","year":"2023","unstructured":"Kawama K, Warabi Y, Bokuda K, Kimura H, Takahashi K. Exacerbation of thymoma-associated myasthenia gravis following efgartigimod treatment related to anti-acetylcholine receptor antibody overshoot: a report of two cases. Cureus. 2023;15(12):e50692.","journal-title":"Cureus"},{"key":"748_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16189","volume":"2","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F, et al. Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center. Eur J Neurol. 2024;2:e16189.","journal-title":"Eur J Neurol"},{"key":"748_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nmd.2024.04.005","volume":"39","author":"K Horiuchi","year":"2024","unstructured":"Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord. 2024;39:37\u201341.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"748_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/biomedicines12061214","volume":"12","author":"S Konno","year":"2024","unstructured":"Konno S, Uchi T, Kihara H, Sugimoto H. Real-world case series of efgartigimod for Japanese generalized myasthenia gravis: well-tailored treatment cycle intervals contribute to sustained symptom control. Biomedicines. 2024;12(6):1214.","journal-title":"Biomedicines"},{"issue":"8","key":"748_CR17","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11(8):2212\u201321.","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"748_CR18","doi-asserted-by":"publisher","first-page":"1472845","DOI":"10.3389\/fneur.2024.1472845","volume":"14","author":"T Nomura","year":"2024","unstructured":"Nomura T, Imamura M, Imura M, Mizutani H, Ueda M. Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients. Front Neurol. 2024;14(15):1472845.","journal-title":"Front Neurol"},{"issue":"3","key":"748_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/mus.28184","volume":"70","author":"L Remijn-Nelissen","year":"2024","unstructured":"Remijn-Nelissen L, Tannemaat MR, Ruiter AM, Campman YJM, Verschuuren JJGM. Efgartigimod in refractory autoimmune myasthenia gravis. Muscle Nerve. 2024;70(3):325\u201332.","journal-title":"Muscle Nerve"},{"issue":"15","key":"748_CR20","doi-asserted-by":"publisher","first-page":"1486659","DOI":"10.3389\/fneur.2024.1486659","volume":"19","author":"F Shi","year":"2024","unstructured":"Shi F, Chen J, Feng L, et al. Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation. Front Neurol. 2024;19(15):1486659.","journal-title":"Front Neurol"},{"issue":"1","key":"748_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","volume":"69","author":"M Singer","year":"2024","unstructured":"Singer M, Khella S, Bird S, et al. Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve. 2024;69(1):87\u201392.","journal-title":"Muscle Nerve"},{"issue":"15","key":"748_CR22","doi-asserted-by":"publisher","first-page":"1418503","DOI":"10.3389\/fimmu.2024.1418503","volume":"29","author":"J Song","year":"2024","unstructured":"Song J, Wang H, Huan X, et al. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol. 2024;29(15):1418503.","journal-title":"Front Immunol"},{"issue":"15","key":"748_CR23","doi-asserted-by":"publisher","first-page":"1407418","DOI":"10.3389\/fneur.2024.1407418","volume":"17","author":"P Wang","year":"2024","unstructured":"Wang P, Zhang B, Yin J, et al. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients. Front Neurol. 2024;17(15):1407418.","journal-title":"Front Neurol"},{"key":"748_CR24","doi-asserted-by":"crossref","unstructured":"Moniz Dion\u00edsio J, Ambrose P, Burke G, et al. Efgartigimod efficacy and safety in refractory myasthenia gravis: UK\u2019s first real-world experience. J Neurol Neurosurg Psychiatry. 2025;96(4):322\u20138.","DOI":"10.1136\/jnnp-2024-334086"},{"key":"748_CR25","unstructured":"Zhu G, Zhou H, Wang W, et al. Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study. Ther Adv Neurol Disord (in press)."},{"issue":"395","key":"748_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578431","volume":"15","author":"Y Hong","year":"2024","unstructured":"Hong Y, Gao L, Huang SQ, et al. Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series. J Neuroimmunol. 2024;15(395):578431.","journal-title":"J Neuroimmunol"},{"issue":"17","key":"748_CR27","doi-asserted-by":"publisher","first-page":"175628642412730","DOI":"10.1177\/17562864241273036","volume":"12","author":"AA Habib","year":"2024","unstructured":"Habib AA, Sacconi S, Antonini G, et al. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase\u00a0III MycarinG study. Ther Adv Neurol Disord. 2024;12(17):17562864241273036.","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00748-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:58:22Z","timestamp":1747663102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00748-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00748-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Haruki Koike is a member of the Editorial Board of Neurology and Therapy. Haruki Koike was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Masaaki Yoshikawa, Yukako Inoue, Koya Tanaka, Keisuke Tsumura, Yuki Hoshino, Chika Shichijo, Toshihiro Ide, Kohei Suzuyama, Megumi Iwasaki, Makoto Eriguchi, Motohiro Yukitake, and Hiroshi Takashima have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments and the Ethical Guidelines for Medical and Health Research Involving Human Subjects endorsed by the Japanese government.\u00a0The study protocol was reviewed and approved by the Ethics Review Committees of the Faculty of Medicine, Saga University (2023-11-R-09), Saga-ken Medical Center Koseikan (24-08-20-01), Karatsu Red Cross Hospital (24I-0801-016), and Takagi Hospital (KR269-1). As a result of the retrospective nature of this study using anonymized data from medical records, opt-out consent, in which participants were provided information about this study and enrolled unless they actively opted out, was applied.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}